Announced details
Polycythemia vera
Among the 6 patients who received PPMX-T003, 4 were confirmed to have remained phlebotomy-free for at least 17 months after completing treatment
6 patients who received PPMX-T003 in the Phase I clinical trial
The principal investigator and medical institution for clinical research involving participants in the Phase I clinical trial conducted by the Company
Department of Hematology and Oncology; principal investigator: Professor Ito Kazuki (伊藤量基)
Clinical research plan number: jRCT1050250129
There is no impact on the earnings forecast for the current fiscal year. The research is expected to contribute to an increase in corporate value over the medium to long term through future business development and other initiatives.
The company does not address Contract Value / Offering price.
Clinical Research Plan Submission and Disclosure System (jRCT)
| Item | Details |
|---|---|
| Names of Products / Services Covered | PPMX-T003 (the drug, T003) |
| Counterparty | Kansai Medical University Hospital |
| Counterparty overview | Department of Hematology and Oncology; principal investigator: Professor Ito Kazuki (伊藤量基) |
| Relationship with the Company | The principal investigator and medical institution for clinical research involving participants in the Phase I clinical trial conducted by the Company |
| Applicable area | Polycythemia vera |
| Registration number and expiry date | Clinical research plan number: jRCT1050250129 |
| Quantitative Effects | Among the 6 patients who received PPMX-T003, 4 were confirmed to have remained phlebotomy-free for at least 17 months after completing treatment |
| Usage history | 6 patients who received PPMX-T003 in the Phase I clinical trial |
| Impact on Business Performance | There is no impact on the earnings forecast for the current fiscal year. The research is expected to contribute to an increase in corporate value over the medium to long term through future business development and other initiatives. |
| Source | Clinical Research Plan Submission and Disclosure System (jRCT) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Clinical research was conducted involving participants in the Phase I clinical trial to explore trends in changes in disease status based on the pharmacodynamic effects of PPMX-T003 and changes in laboratory test values.